Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design

The primary goal of rational drug discovery is the identification of selective ligands which act on single or multiple drug targets to achieve the desired clinical outcome through the exploration of total chemical space. To identify such desired compounds, computational approaches are necessary in predicting their drug-like properties. G Protein-Coupled Receptors (GPCRs) represent one of the largest and most important integral membrane protein families. These receptors serve as increasingly attractive drug targets due to their relevance in the treatment of various diseases, such as inflammatory disorders, metabolic imbalances, cardiac disorders, cancer, monogenic disorders, etc. In the last decade, multitudes of three-dimensional (3D) structures were solved for diverse GPCRs, thus referring to this period as the “golden age for GPCR structural biology.” Moreover, accumulation of data about the chemical properties of GPCR ligands has garnered much interest toward the exploration of GPCR chemical space. Due to the steady increase in the structural, ligand, and functional data of GPCRs, several cheminformatics approaches have been implemented in its drug discovery pipeline. In this review, we mainly focus on the cheminformatics-based paradigms in GPCR drug discovery. We provide a comprehensive view on the ligand– and structure-based cheminformatics approaches which are best illustrated via GPCR case studies. Furthermore, an appropriate combination of ligand-based knowledge with structure-based ones, i.e., integrated approach, which is emerging as a promising strategy for cheminformatics-based GPCR drug design is also discussed.

[1]  László Kovács,et al.  Structure-Based Consensus Scoring Scheme for Selecting Class A Aminergic GPCR Fragments , 2016, J. Chem. Inf. Model..

[2]  T. Clark G-Protein coupled receptors: answers from simulations , 2017, Beilstein journal of organic chemistry.

[3]  Kai-Wei Chang,et al.  iScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan , 2011, J. Comput. Aided Mol. Des..

[4]  Damián Palomba,et al.  Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models. , 2015, Chemical communications.

[5]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[6]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[7]  Guodong Liu,et al.  A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[8]  P. Jenner Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease , 2005, Expert opinion on investigational drugs.

[9]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[10]  Asher Mullard,et al.  The drug-maker's guide to the galaxy , 2017, Nature.

[11]  Richard S Judson,et al.  In Silico Study of In Vitro GPCR Assays by QSAR Modeling. , 2016, Methods in molecular biology.

[12]  Alexandre Varnek,et al.  Chemoinformatics approaches to virtual screening , 2008 .

[13]  Woody Sherman,et al.  Selecting an Optimal Number of Binding Site Waters To Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor , 2014, J. Chem. Inf. Model..

[14]  Bryan L. Roth,et al.  Structure of the human smoothened receptor bound to an antitumour agent , 2013, Nature.

[15]  I. Piedade,et al.  In silico prediction of , 2014 .

[16]  A. Leslie,et al.  Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.

[17]  K. Garcia,et al.  Adrenaline-activated structure of the β2-adrenoceptor stabilized by an engineered nanobody , 2013, Nature.

[18]  Peter Kolb,et al.  Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics , 2016, ChemMedChem.

[19]  Albert C. Pan,et al.  Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.

[20]  Pankaj R. Daga,et al.  Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification , 2014, J. Chem. Inf. Model..

[21]  John B. O. Mitchell Machine learning methods in chemoinformatics , 2014, Wiley interdisciplinary reviews. Computational molecular science.

[22]  Brian K Shoichet,et al.  Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.

[23]  Alexander Heifetz,et al.  Computational Methods for GPCR Drug Discovery , 2018, Methods in Molecular Biology.

[24]  Ralf C. Kling,et al.  GPCR crystal structures: Medicinal chemistry in the pocket. , 2015, Bioorganic & medicinal chemistry.

[25]  Xiao-dan Li,et al.  Discovery of novel antagonists of human neurotensin receptor 1 on the basis of ligand and protein structure. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[26]  Paul A. Insel,et al.  G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? , 2018, Molecular Pharmacology.

[27]  Pablo R. Duchowicz,et al.  Software and Web Resources for Computer-Aided Molecular Modeling and Drug Discovery , 2016 .

[28]  Krzysztof Palczewski,et al.  Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.

[29]  Peter Ertl,et al.  Relationships between Molecular Complexity, Biological Activity, and Structural Diversity , 2006, J. Chem. Inf. Model..

[30]  Christopher G. Tate,et al.  Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.

[31]  Ali Jazayeri,et al.  Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.

[32]  T. Nikolskaya,et al.  Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  A. Kruse,et al.  Structural Basis for G Protein-Coupled Receptor Activation. , 2017, Biochemistry.

[34]  Ali Jazayeri,et al.  From G Protein-coupled Receptor Structure Resolution to Rational Drug Design* , 2015, The Journal of Biological Chemistry.

[35]  J. Vilardaga Studying ligand efficacy at G protein-coupled receptors using FRET. , 2011, Methods in molecular biology.

[36]  Markus Hartenfeller,et al.  DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..

[37]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[38]  Dingfeng Wu,et al.  The recent progress in proteochemometric modelling: focusing on target descriptors, cross‐term descriptors and application scope , 2017, Briefings Bioinform..

[39]  Albert C. Pan,et al.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.

[40]  Ali Jazayeri,et al.  Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. , 2017, Chemical reviews.

[41]  T. Schwartz,et al.  Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91 , 2017, Molecular metabolism.

[42]  Mark McGann,et al.  FRED and HYBRID docking performance on standardized datasets , 2012, Journal of Computer-Aided Molecular Design.

[43]  P. Argos,et al.  The structure of bovine rhodopsin , 2004, Biophysics of structure and mechanism.

[44]  Xiang-Qun Xie,et al.  Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands , 2013, Front. Pharmacol..

[45]  D. Sejer Pedersen,et al.  Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. , 2017, Journal of medicinal chemistry.

[46]  Didier Rognan,et al.  Structure‐Based Discovery of Allosteric Modulators of Two Related Class B G‐Protein‐Coupled Receptors , 2011, ChemMedChem.

[47]  Hiromasa Kaneko,et al.  A Mini-review on Chemoinformatics Approaches for Drug Discovery , 2015 .

[48]  Chris de Graaf,et al.  Snooker: A Structure-Based Pharmacophore Generation Tool Applied to Class A GPCRs , 2011, J. Chem. Inf. Model..

[49]  William Thomsen,et al.  Functional assays for screening GPCR targets. , 2005, Current opinion in biotechnology.

[50]  Vadim Cherezov,et al.  Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.

[51]  Xi Zhang,et al.  Seven perspectives on GPCR H/D-exchange proteomics methods , 2017, F1000Research.

[52]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[53]  Masahiko Nakatsui,et al.  Chemical Genomics Approach for GPCR-Ligand Interaction Prediction and Extraction of Ligand Binding Determinants , 2013, J. Chem. Inf. Model..

[54]  L. Luck,et al.  Molecular modeling of estrogen receptor using molecular operating environment , 2007, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.

[55]  Sean Ekins,et al.  Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. , 2012, Drug discovery today.

[56]  David Rodríguez,et al.  Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor , 2015, J. Chem. Inf. Model..

[57]  Maria F. Sassano,et al.  Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor , 2013, ACS chemical biology.

[58]  Y. Liu,et al.  Methods used to study the oligomeric structure of G-protein-coupled receptors , 2017, Bioscience reports.

[59]  Woody Sherman,et al.  Molecular dynamics techniques for modeling G protein-coupled receptors. , 2016, Current opinion in pharmacology.

[60]  Ruben Abagyan,et al.  Pocketome: an encyclopedia of small-molecule binding sites in 4D , 2011, Nucleic Acids Res..

[61]  Ali Jazayeri,et al.  Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). , 2015, Journal of medicinal chemistry.

[62]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[63]  Arthur Christopoulos,et al.  Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening , 2017, PloS one.

[64]  Jürgen Bajorath,et al.  Chemoinformatics : concepts, methods, and tools for drug discovery , 2004 .

[65]  C. Tautermann Impact, determination and prediction of drug-receptor residence times for GPCRs. , 2016, Current opinion in pharmacology.

[66]  Sean Ekins,et al.  A quality alert and call for improved curation of public chemistry databases. , 2011, Drug discovery today.

[67]  Olivier Michielin,et al.  SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening , 2016, J. Chem. Inf. Model..

[68]  Yanli Wang,et al.  Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.

[69]  David Rodríguez,et al.  Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists. , 2016, ACS chemical biology.

[70]  G. Wynne,et al.  Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists , 2015, Bioorganic & medicinal chemistry.

[71]  Peter Gmeiner,et al.  Muscarinic Receptors as Model Targets and Antitargets for Structure-Based Ligand Discovery , 2013, Molecular Pharmacology.

[72]  J. Varghese,et al.  Development of neuraminidase inhibitors as anti‐influenza virus drugs , 1999 .

[73]  C. Lemmen,et al.  FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.

[74]  Henry Lin,et al.  Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.

[75]  F. Brown Chapter 35 – Chemoinformatics: What is it and How does it Impact Drug Discovery. , 1998 .

[76]  Albert C. Pan,et al.  Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.

[77]  J. Pin,et al.  A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. , 2010, Journal of medicinal chemistry.

[78]  Terry Kenakin,et al.  Pharmacology in Drug Discovery and Development : Understanding Drug Response Ed. 2 , 2016 .

[79]  Paul D Lyne,et al.  Structure-based virtual screening: an overview. , 2002, Drug discovery today.

[80]  Jean-François Gibrat,et al.  Automatic modeling of mammalian olfactory receptors and docking of odorants. , 2012, Protein engineering, design & selection : PEDS.

[81]  Alexander Tropsha,et al.  Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..

[82]  Ruben Abagyan,et al.  Docking and scoring with ICM: the benchmarking results and strategies for improvement , 2012, Journal of Computer-Aided Molecular Design.

[83]  Paolo Carloni,et al.  GOMoDo: A GPCRs Online Modeling and Docking Webserver , 2013, PloS one.

[84]  David E. Gloriam,et al.  Integrating structural and mutagenesis data to elucidate GPCR ligand binding. , 2016, Current opinion in pharmacology.

[85]  Sun Choi,et al.  Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. , 2018, Journal of medicinal chemistry.

[86]  J. Andrew McCammon,et al.  Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor , 2016, Proceedings of the National Academy of Sciences.

[87]  Alexander Golbraikh,et al.  Application of Quantitative Structure–Activity Relationship Models of 5-HT1A Receptor Binding to Virtual Screening Identifies Novel and Potent 5-HT1A Ligands , 2014, J. Chem. Inf. Model..

[88]  Vincent Le Guilloux,et al.  Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.

[89]  Olivier Sperandio,et al.  FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects , 2008, BMC Bioinformatics.

[90]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[91]  Ali Jazayeri,et al.  Intracellular allosteric antagonism of the CCR9 receptor , 2016, Nature.

[92]  D Sam Paul,et al.  MOLS 2.0: software package for peptide modeling and protein–ligand docking , 2016, Journal of Molecular Modeling.

[93]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[94]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[95]  B. Neustadt,et al.  Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. , 2007, Bioorganic & medicinal chemistry letters.

[96]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[97]  Weijun Xu,et al.  Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 , 2015, J. Chem. Inf. Model..

[98]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[99]  Igor I. Baskin,et al.  Machine Learning Methods for Property Prediction in Chemoinformatics: Quo Vadis? , 2012, J. Chem. Inf. Model..

[100]  Gebhard F. X. Schertler,et al.  Projection structure of rhodopsin , 1993, Nature.

[101]  E. Kostenis,et al.  Functional selectivity and dualsteric/bitopic GPCR targeting , 2017, Current opinion in pharmacology.

[102]  Arthur Christopoulos,et al.  Phase-plate cryo-EM structure of a class B GPCR-G protein complex , 2017, Nature.

[103]  X. Xie,et al.  Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5 , 2017, The AAPS Journal.

[104]  Naomi R. Latorraca,et al.  Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors , 2017, Cell.

[105]  Thomas Lengauer,et al.  Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.

[106]  R. Abagyan,et al.  Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.

[107]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[108]  Yong Seo Cho,et al.  Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach , 2016, Chemical biology & drug design.

[109]  Nathan Robertson,et al.  Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .

[110]  David E. Gloriam,et al.  Pharmacogenomics of GPCR Drug Targets , 2018, Cell.

[111]  K. Chung,et al.  Conformational analysis of g protein-coupled receptor signaling by hydrogen/deuterium exchange mass spectrometry. , 2015, Methods in enzymology.

[112]  G. Keserű,et al.  Fragment-based lead discovery on G-protein-coupled receptors , 2013, Expert opinion on drug discovery.

[113]  David E. Gloriam,et al.  Trends in GPCR drug discovery: new agents, targets and indications , 2017, Nature Reviews Drug Discovery.

[114]  Ruben Abagyan,et al.  Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.

[115]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[116]  Oliver Koch,et al.  What Can We Learn from Bioactivity Data? Chemoinformatics Tools and Applications in Chemical Biology Research. , 2017, ACS chemical biology.

[117]  Sid Topiol,et al.  Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.

[118]  Ruth Nussinov,et al.  Deterministic Pharmacophore Detection Via Multiple Flexible Alignment of Drug-Like Molecules , 2007, RECOMB.

[119]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[120]  Sun Choi,et al.  Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches. , 2017, Current medicinal chemistry.

[121]  A. Doré,et al.  Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.

[122]  T. S. Kobilka,et al.  Cryo-EM structure of the activated GLP-1 receptor in complex with G protein , 2017, Nature.

[123]  Harpreet Singh,et al.  Software and Web Resources for Computer-Aided Molecular Modeling and Drug Discovery , 2016 .

[124]  R Sowdhamini,et al.  Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules , 2016, Journal of biomolecular structure & dynamics.

[125]  Pekka Tiikkainen,et al.  Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..

[126]  Raymond C. Stevens,et al.  Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor*♦ , 2015, The Journal of Biological Chemistry.

[127]  H. V. van Vlijmen,et al.  Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development , 2011, PloS one.

[128]  Anil K. Saxena,et al.  Integration on Ligand and Structure Based Approaches in GPCRs , 2017 .

[129]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[130]  Tudor I. Oprea,et al.  WOMBAT: World of Molecular Bioactivity , 2005 .

[131]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[132]  Woody Sherman,et al.  Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation , 2016, ACS omega.

[133]  Minsup Kim,et al.  Incorporating QM and solvation into docking for applications to GPCR targets. , 2016, Physical chemistry chemical physics : PCCP.

[134]  Arthur Christopoulos,et al.  A kinetic view of GPCR allostery and biased agonism. , 2017, Nature chemical biology.

[135]  Philippe Chavatte,et al.  Virtual Screening of CB2 Receptor Agonists from Bayesian Network and High‐Throughput Docking: Structural Insights into Agonist‐Modulated GPCR Features , 2013, Chemical biology & drug design.

[136]  Jesús A Izaguirre,et al.  Characterization of the Anopheles gambiae octopamine receptor and discovery of potential agonists and antagonists using a combined computational-experimental approach , 2014, Malaria Journal.

[137]  R. Stevens,et al.  How Ligands Illuminate GPCR Molecular Pharmacology , 2017, Cell.

[138]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[139]  Christopher W Murray,et al.  Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.

[140]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[141]  T. Lundstedt,et al.  Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.

[142]  J. Baldwin The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.

[143]  Luis G Valerio,et al.  Chemoinformatics and chemical genomics: potential utility of in silico methods , 2012, Journal of applied toxicology : JAT.

[144]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[145]  Ajay N. Jain Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[146]  Sun Choi,et al.  In silico classification of adenosine receptor antagonists using Laplacian-modified naïve Bayesian, support vector machine, and recursive partitioning. , 2010, Journal of molecular graphics & modelling.

[147]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[148]  Isidro Cortes-Ciriano,et al.  Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects , 2015 .

[149]  Satoshi Niijima,et al.  GLIDA: GPCR—ligand database for chemical genomics drug discovery—database and tools update , 2007, Nucleic Acids Res..

[150]  J. Qian,et al.  Visualization of arrestin recruitment by a G Protein-Coupled Receptor , 2014, Nature.

[151]  Stefano Costanzi,et al.  Computational studies to predict or explain G protein coupled receptor polypharmacology. , 2014, Trends in pharmacological sciences.

[152]  Emmanuel Bresso,et al.  GPCRs from fusarium graminearum detection, modeling and virtual screening - the search for new routes to control head blight disease , 2016, BMC Bioinformatics.

[153]  A. Hauser,et al.  Identification of Histamine H3 Receptor Ligands Using a New Crystal Structure Fragment-based Method , 2017, Scientific Reports.

[154]  Manfred Burghammer,et al.  Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.

[155]  Chris de Graaf,et al.  Function-specific virtual screening for GPCR ligands using a combined scoring method , 2016, Scientific Reports.

[156]  Garth J. Williams,et al.  Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser , 2014, Nature.

[157]  E. Lionta,et al.  Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.

[158]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[159]  A Wlodawer,et al.  Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.

[160]  Petra Schneider,et al.  Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.

[161]  Roderick E Hubbard,et al.  Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.

[162]  Márton Vass,et al.  Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors. , 2014, ACS medicinal chemistry letters.

[163]  Woody Sherman,et al.  In search of novel ligands using a structure-based approach: a case study on the adenosine A2A receptor , 2016, Journal of Computer-Aided Molecular Design.

[164]  Arthur Christopoulos,et al.  Improving virtual screening of G protein-coupled receptors via ligand-directed modeling , 2017, PLoS Comput. Biol..

[165]  B. Neustadt Potent, Selective, and Orally Active Adenosine A2A Receptor Antagonists: Arylpiperazine Derivatives of Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidines. , 2007 .

[166]  J. Reymond The chemical space project. , 2015, Accounts of chemical research.

[167]  M. Cui,et al.  In silico prediction of multiple-category classification model for cytochrome P450 inhibitors and non-inhibitors using machine-learning method$ , 2017, SAR and QSAR in environmental research.

[168]  Hualiang Jiang,et al.  Two disparate ligand-binding sites in the human P2Y1 receptor , 2015, Nature.

[169]  Ajay N. Jain,et al.  Surflex-Dock: Docking benchmarks and real-world application , 2012, Journal of Computer-Aided Molecular Design.

[170]  Tudor I. Oprea,et al.  Chemography: the Art of Navigating in Chemical Space , 2000 .

[171]  Zhiwei Cao,et al.  Study on human GPCR-inhibitor interactions by proteochemometric modeling. , 2013, Gene.

[172]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[173]  Jihye Seong,et al.  Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist , 2016, Journal of Computer-Aided Molecular Design.

[174]  George Khelashvili,et al.  GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base , 2010, Bioinform..

[175]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[176]  Adriaan P. IJzerman,et al.  Complementarity between in Silico and Biophysical Screening Approaches in Fragment-Based Lead Discovery against the A2A Adenosine Receptor , 2013, J. Chem. Inf. Model..

[177]  Gisbert Schneider,et al.  Multidimensional de novo design reveals 5-HT2B receptor-selective ligands. , 2015, Angewandte Chemie.

[178]  A. Bayoumi,et al.  Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology , 2017, Biomolecules & therapeutics.

[179]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[180]  Ruben Abagyan,et al.  Spatial chemical distance based on atomic property fields , 2010, J. Comput. Aided Mol. Des..

[181]  S. Moro,et al.  Advances in Computational Techniques to Study GPCR-Ligand Recognition. , 2015, Trends in pharmacological sciences.

[182]  K. Jacobson,et al.  Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site , 2017, Scientific Reports.

[183]  J. Violin,et al.  Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. , 2011, Circulation research.

[184]  Chaok Seok,et al.  Galaxy7TM: flexible GPCR–ligand docking by structure refinement , 2016, Nucleic Acids Res..

[185]  Tina Ritschel,et al.  Molecular interaction fingerprint approaches for GPCR drug discovery. , 2016, Current opinion in pharmacology.

[186]  R. Smits,et al.  Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A , 2011, Bioorganic & medicinal chemistry letters.

[187]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[188]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[189]  Alexander Tropsha,et al.  Comparative Analysis of QSAR‐based vs. Chemical Similarity Based Predictors of GPCRs Binding Affinity , 2016, Molecular informatics.

[190]  C. Hoffmann,et al.  Intramolecular and Intermolecular FRET Sensors for GPCRs - Monitoring Conformational Changes and Beyond. , 2017, Trends in pharmacological sciences.

[191]  Ruben Abagyan,et al.  Identifying ligands at orphan GPCRs: current status using structure‐based approaches , 2016, British journal of pharmacology.

[192]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[193]  S. P. Andrews,et al.  Structure‐Based and Fragment‐Based GPCR Drug Discovery , 2014, ChemMedChem.

[194]  D. E. Nichols,et al.  Crystal Structure of an LSD-Bound Human Serotonin Receptor , 2017, Cell.

[195]  Márton Vass,et al.  Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. , 2014, European journal of medicinal chemistry.

[196]  David S Wishart,et al.  Introduction to cheminformatics. , 2007, Current protocols in bioinformatics.